Encyclopedia of Signaling Molecules

Living Edition
| Editors: Sangdun Choi

FAP

Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-6438-9_101596-1

Synonyms

Historical Background

Fibroblast activation protein (FAP; FAP-α; seprase) is a type II 95 kDa post-proline cleaving atypical serine protease, closely related to the dipeptidyl peptidases (DPP) DPP-4, DPP-8, and DPP-9 in the prolyl oligopeptidase gene and enzyme family. FAP is conserved throughout chordate evolution, with homologs in human (hFAP), mouse (mFAP), and Xenopus laevis (89 % and 50 % protein sequence identity to hFAP, respectively). FAP expression correlates with tissue remodeling events (Hamson et al. 2014; Liu et al. 2015; Jiang et al. 2016). FAP is also phylogenetically linked to the prototype prolyl oligopeptidase, which is prolyl endopeptidase (PEP; PREP). FAP has both an endopeptidase activity that is similar to but distinct from that of PEP and a DPP activity that is similar to those of DPP4, DPP8, and DPP9 as well as the unrelated peptidase DPP7 (DPP-II).

FAP was originally...

Keywords

Sarcoma Polypeptide Osteoarthritis Trypsin Fibril 
This is a preview of subscription content, log in to check access

Notes

Acknowledgment

MDG is supported by grants 1105238 and 1113842 from the Australian National Health and Medical Research Council.

References

  1. Aertgeerts K, Levin I, Shi L, Snell GP, Jennings A, Prasad GS, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein {alpha}. J Biol Chem. 2005;280:19441–4. doi:10.1074/jbc.C500092200.CrossRefPubMedGoogle Scholar
  2. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257–66. doi:10.1158/1535-7163.mct-11-0340.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Christiansen VJ, Jackson KW, Lee KN, McKee PA. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys. 2007;457:177–86. doi:10.1016/j.abb.2006.11.006.CrossRefPubMedGoogle Scholar
  4. Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, et al. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J Biol Chem. 2016;291:5986–96. doi:10.1074/jbc.M115.710582.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Fan M-H, Zhu Q, Li H-H, Ra H-J, Majumdar S, Gulick DL, et al. Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice. J Biol Chem. 2016;291:8070–89. doi:10.1074/jbc.M115.701433.CrossRefPubMedGoogle Scholar
  6. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87:7235–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–63. doi:10.1002/prca.201300095.CrossRefPubMedGoogle Scholar
  8. Jiang G-M, Xu W, Du J, Zhang K-S, Zhang Q-G, Wang X-W, et al. The application of the fibroblast activation protein α-targeted immunotherapy strategy. Oncotarget. 2016;7(22):33472–82. doi:10.18632/oncotarget.8098.PubMedPubMedCentralGoogle Scholar
  9. Keane FM, Nadvi NA, Yao T-W, Gorrell MD. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS J. 2011;278:1316–32. doi:10.1111/j.1742-4658.2011.08051.x.CrossRefPubMedGoogle Scholar
  10. Keane FM, Yao T-W, Seelk S, Gall MG, Chowdhury S, Poplawski SE, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio. 2014;4:43–54. doi:10.1016/j.fob.2013.12.001.CrossRefGoogle Scholar
  11. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood. 2006;107:1397–404. doi:10.1182/blood-2005-08-3452.CrossRefPubMedGoogle Scholar
  12. Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One. 2015;10:e0116683. doi:10.1371/journal.pone.0116683.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Lo A, Wang L-CS, Scholler J, Monslow J, Avery D, Newick K, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2015;75:2800–10. doi:10.1158/0008-5472.can-14-3041.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Meng M, Wang W, Yan J, Tan J, Liao L, Shi J, et al. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model. Tumor Biol. 2016;37:10317–27. doi:10.1007/s13277-016-4825-4.CrossRefGoogle Scholar
  15. Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen WT. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem. 1997;272:7595–601.CrossRefPubMedGoogle Scholar
  16. Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BK, Garin-Chesa P, et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer. 1994;58:385–92.CrossRefPubMedGoogle Scholar
  17. Wang XM, Yu DMT, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion and migration by the LX-2 human stellate cell line. Hepatology. 2005;42:935–45. doi:10.1002/hep.20853.CrossRefPubMedGoogle Scholar
  18. Wilson CH, Zhang HE, Gorrell MD, Abbott CA. Dipeptidyl peptidase substrate discovery: current progress and the application of mass spectrometry – based approaches. Biol Chem. 2016;397:837–56. doi:10.1515/hsz-2016-0174.CrossRefPubMedGoogle Scholar
  19. Zi F, He J, He D, Li YI, Yang LI, Cai Z. Fibroblast activation protein α in tumor microenvironment: recent progression and implications. Mol Med Rep. 2015;11:3203–11. doi:10.3892/mmr.2015.3197.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2016

Authors and Affiliations

  1. 1.Centenary Institute and Sydney Medical SchoolThe University of SydneyNewtownAustralia